tldrdaily.news logo
Tag

Pharmaceuticalindustry

All articles tagged with #pharmaceuticalindustry

business1 year ago

RFK Jr.'s HHS Appointment Sparks Health Sector Concerns

Health stocks fell sharply after Donald Trump nominated vaccine skeptic Robert F. Kennedy Jr. as US Health Secretary, raising concerns about potential regulatory changes. Shares in major pharmaceutical companies like Pfizer, Moderna, AstraZeneca, and GSK dropped significantly, reflecting investor uncertainty. Kennedy's stance against "Big Pharma" and his history of spreading controversial health information have spooked the market, despite unclear policy directions. The nomination, if confirmed, could signal a shift from previous administrations' approaches to healthcare regulation.

via BBC.com|
#business#healthstocks#marketreaction
business1 year ago

RFK Jr.'s HHS Nomination Shakes Markets and Sparks Controversy

Vaccine and pharmaceutical stocks fell sharply after Donald Trump nominated vaccine skeptic Robert F. Kennedy Jr. as the head of the US Department of Health and Human Services. Kennedy's controversial views on vaccines and the FDA have raised concerns about potential policy changes, impacting companies like Moderna, Pfizer, GSK, and Sanofi. The nomination is expected to face a challenging Senate confirmation process. Despite the market reaction, some industry insiders believe Kennedy's ideas are unlikely to become policy.

via Financial Times|
#business#fda#pharmaceuticalindustry
health-and-pharmaceuticals2 years ago

"Eli Lilly's New Weight Loss Drug Strategy Shakes Up Market, Despite Pushback on Cosmetic Use"

Eli Lilly has launched a new direct-to-consumer service, LillyDirect, offering telehealth prescriptions and home delivery for certain drugs, including the weight loss treatment Zepbound. This move, a first for a major drugmaker, aims to bypass traditional drug distribution systems and provide more accessible and transparent pricing. While it may not immediately disrupt the industry, it could lead to more pharmaceutical companies adopting similar models, increasing pressure on the current complex drug supply chain. Analysts believe that while the traditional infrastructure involving PBMs will remain, Eli Lilly's approach could streamline access to medications and potentially influence drug pricing and distribution practices.

via CNBC|
##directtoconsumer#drugpricing
business-and-finance2 years ago

"Novo Nordisk Strikes Lucrative Biotech Alliances, Fuels Obesity Drug Race and Skyrockets Omega Stock"

Novo Nordisk has entered into a $1.1 billion research and development deal with two US biotech firms, Omega Therapeutics and Cellarity, to enhance its portfolio in obesity drugs and treatments for Metabolic Dysfunction-associated Steatohepatitis (MASH). The partnerships, which are part of a strategic move to maintain a competitive edge in the rapidly growing obesity drug market, have been positively received by the market, with Novo Nordisk's stock seeing an uptick following the announcement.

via Yahoo Finance|
##biotechpartnerships#business-and-finance